Figure 3 from Exosomal Thomsen–Friedenreich Glycoantigen: A New Liquid Biopsy Biomarker for Lung and Breast Cancer Diagnoses

ROC analysis to evaluate diagnostic performance of exosomal TF-Ag-α in lung cancer. ROC curves of comparisons between all patients with lung cancer (n = 40) and normal controls (n = 41; A); early-stage lung cancer (stage I/II, n = 18) and normal controls (n = 41; B); late-stage lung cancer (stage III/IV, n = 22) and normal controls (n = 41; C); NSCLC (n = 30) and normal controls (n = 41; D); and SCLC (n = 10) and normal controls (n = 41; E). Normal controls included 20 low-risk patients and 21 high-risk patients. The sensitivity (SEN), specificity (SPE), AUC, and cutoff values of exosomal TF-Ag-α for each comparison are summarized in F.